| | A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to . . . |
Ongoing |
14 Aug 2020 |
| | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a . . . |
Ongoing |
18 May 2020 |
| | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine + Cisplatin for Neoadjuvant Treatment Followed by Dur . . . |
Ongoing |
19 May 2020 |
| | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanc . . . |
Ongoing |
18 May 2020 |
| | A Phase IV Interventional Safety, Efficacy and Quality of Life Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) . . . |
Completed |
05 Nov 2020 |
| | A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj. {fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [r . . . |
Ongoing |
14 May 2020 |
| | A prospective, Phase I, randomized, controlled, open label study to assess the reactogenicity, safety and immunogenicity of a combined liquid DTwP-rHepB-Hib-IPV vaccine when administered to healthy ch . . . |
Completed |
02 Aug 2019 |
| | A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI) and best availability therapy for the treatment of serious inf . . . |
Pending |
22 Apr 2021 |
| | A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caus . . . |
Pending |
07 May 2021 |
| | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular . . . |
Pending |
21 May 2021 |
| | A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephr . . . |
Completed |
02 Mar 2020 |
| | A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis . . . |
Ongoing |
02 Mar 2020 |
| | A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter . . . |
Pending |
30 Mar 2021 |
| | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe . . . |
Completed |
23 Sep 2019 |
| | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients wi . . . |
Ongoing |
03 Jul 2020 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
30 Mar 2021 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
31 Mar 2021 |
| | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metasta . . . |
Ongoing |
09 Sep 2020 |
| | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab . . . |
Ongoing |
10 Oct 2019 |
| | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older. . . . |
Ongoing |
25 Jan 2021 |
| | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in Asian subjects (≥16 to 80 years of age) with parti . . . |
Ongoing |
26 Feb 2021 |
| | A randomized, double-blind, placebo-controlled, parallel group, multi-center trial of pregabalin as adjunctive therapy in pediatric and adult subjects with primary generalized tonic-clonic seizures . . . |
Completed |
17 Jul 2019 |
| | A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit . . . |
Ongoing |
30 Jul 2020 |
| | A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenecity of JS016 (Recombinant Human Anti-SA . . . |
Ongoing |
28 May 2021 |
| | A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo with Chemotherapy . . . |
Pending |
12 Aug 2020 |